✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
REL-1017 is an investigational drug.
There have been 39 clinical trials for REL-1017. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Depressive Disorder, Major. The leading clinical trial sponsors are Relmada Therapeutics, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
Recent Clinical Trials for REL-1017
|Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections||Merck Sharp & Dohme Corp.||Phase 4|
|Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections||Atrium Health||Phase 4|
|A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)||Relmada Therapeutics, Inc.||Phase 3|